September is World Alzheimer’s Month. Caring for those with Alzheimer’s disease takes education, knowledge, understanding, and hope to find solutions to lessen the impact of the disease. Research, studies, and trials are continually evolving, so to highlight recent progress, we wanted to explain current information.
The Alzheimer’s Association describes Alzheimer’s disease as a type of dementia that affects memory, thinking, and behavior. It’s also a progressive disease that causes symptoms to worsen over time. Older adults in the early stages of Alzheimer’s might notice mild memory loss. In contrast, those in the late stages can lose the ability to carry on a conversation or even respond to their environment. Alzheimer’s disease affects one in nine people age 65 and older and women more significantly than men. Although there’s been significant research on Alzheimer’s, there is no cure because of the complexity of the illness. However, that hasn’t stopped medical professionals from continuing their Alzheimer’s research. Join us as we discuss recent Alzheimer’s research trends.
How Is Alzheimer’s Disease Treated?
Alzheimer’s is characterized by abnormal changes in the brain. While scientists do not know what exactly causes Alzheimer’s, most experts believe plaques and tangles play a significant role. Plaques, which are deposits of a protein fragment, build up in the spaces between nerve cells, and tangles, which are twisted fibers of a different protein, develop more frequently and predictably in the brain of someone who has Alzheimer’s disease. Because Alzheimer’s can look different in each individual, it’s highly unlikely that one drug would treat all individuals with the disease. However, because of research and clinical trials, scientists have made significant progress in understanding the memory problems associated with Alzheimer’s. While there are several prescription drugs to help manage the symptoms of Alzheimer’s, none have been able to cure it or even stop the progression of the disease. The first FDA-approved therapy that addresses the underlying biology of Alzheimer’s has recently received approval as treatment. Aducanumab works to remove amyloid, one of the hallmarks of Alzheimer’s, from the brain, which can help reduce cognitive and functional decline for those with early-stage Alzheimer’s.
In addition to the recent approval of Aducanumab, international researchers have made significant progress in learning more about Alzheimer’s disease this past year. Researchers from Tokyo Metropolitan University recently discovered that a specific element of a key protein, tau, may cause the proteins to accumulate in the brain. These deposits can trigger Alzheimer’s. While the tau protein is key to the healthy function of certain cells, when the microtubules, or “cell highways,” they create aren’t formed properly, it can cause a wide range of neurodegenerative diseases. To learn how to identify when a tau protein isn’t working properly, researchers are using different organisms, such as the Drosophila fruit fly.
An upcoming research study at the University of Arizona Health Sciences will focus on identifying various therapies that prevent or delay the progression of Alzheimer’s. The study will focus on understanding one of the strongest genetic risk factors, ApoE4, a key element in how our bodies metabolize fat and brain energy. This study is expected to allow researchers to understand more thoroughly and develop interventions for those with late-onset Alzheimer’s.
Trials and Research of Alzheimer’s Disease
According to the Alzheimer’s Association, clinical trials allow researchers to conduct studies with human volunteers to determine whether a possible treatment is safe and effective. Without the help of participants and clinical research, there can be no treatments, preventions, or cures. New drugs must complete a series of phases before being approved by the Food and Drug Administration. The treatment must perform well enough to move on to the next phase.
- Phase I trials. The first stage of testing typically involves 100 volunteers or less and looks at the risks and side effects of a drug. These participants are usually healthy volunteers who haven’t been diagnosed with Alzheimer’s.
- Phase II trials. This phase requires volunteers who have been diagnosed with the condition the drug is designed to treat. These studies help provide information about the treatment’s safety and help to determine the best dosage of the medication.
- Phase III trials. The third stage requires a research team to enroll several hundred to thousands of volunteers at multiple sites worldwide. This provides evidence for safety and effectiveness that will be considered by the Food and Drug Administration (FDA).
- Phase IV trials. After the FDA approves a drug, researchers must continue to monitor the health of those taking the medication to gain insight into its long-term safety and effectiveness.
Getting Involved in a Clinical Trial
If you or a loved one is interested in participating in or learning more about a clinical trial, there are various ways to get involved. The first option is to speak with your healthcare provider. Because your doctor has a deep understanding of your medical information, they may be able to connect you with an appropriate clinical trial.
In addition, TrialMatch, operated by the Alzheimer’s Association, connects individuals to clinical studies in their area. To be connected within TrialMatch, you’ll need your clinical diagnosis, tests used to diagnose the stage of the disease, and a current Alzheimer’s medication list.
Questions to Consider
Before you commit to participating in a clinical trial, it’s important to understand the trial information by making an appointment with your healthcare provider. The National Institute on Aging recommends that individuals considering participation in a clinical trial ask the research team these questions:
- What’s the purpose of the study?
- What tests and treatments will be given?
- What are the risks and side effects?
- What are the benefits of the research?
- How much time is required?
- How long will the study run?
- How will the trial affect my daily life?
- Will I learn my results?
- Are expenses reimbursed?
- Will I be paid?
Living with Alzheimer’s at Inspīr Carnegie Hill
Memory care residents in our Oceana program have access to high-quality medical care and staff trained specifically in dementia care. We offer personalized wellness-focused programming, luxury-level service, and all the comforts of the Inspīr lifestyle in a secure setting. Support groups, access to clinical trial information, and Alzheimer’s medication is available to all residents living with Alzheimer’s.